PeptidesInfo
Benefits

Are Peptides Worth It? A Framework for Deciding

Whether a peptide is worth it depends on four things: what benefit is proven, in whom, for how long, and whether the effect lasts after you stop. Here is that framework applied to every peptide we cover.

Abstract lattice illustration for the peptide decision framework
Contents
  1. The four questions
  2. Applying it
  3. Passes all four, with a subscription caveat
  4. Passes on cost, modest on effect
  5. Stops at question one
  6. The framework as a table
  7. The question behind the question
  8. What we cannot tell you
  9. Where to go next

Key findings

  1. 1Four questions settle most of it: what benefit is proven, in whom, over what timeframe, and does it persist after stopping.
  2. 2The peptides that pass all four are the approved ones with large trials — and even they require continued treatment to hold the benefit.
  3. 3Collagen peptides pass on cost and evidence but deliver small effects over months, which is a different value proposition from a drug.
  4. 4For BPC-157, TB-500 and the growth-hormone secretagogues, question one has no answer yet, so the remaining three cannot be assessed.
  5. 5A benefit demonstrated in a trial belongs to the trial's product, dose and population — a different product of unverified content inherits none of it.

Evidence level

Conflicting evidence

This is a decision framework rather than a claim about a single peptide. It applies four questions to each peptide we profile, using the evidence grade and trial population recorded on that peptide's page.

Regulatory status

Status requires verification

Four of the peptides assessed are FDA-approved for specific uses; the rest are not approved for any use. Each peptide's own status is on its profile.

"Is it worth it" is really four questions wearing a trench coat. Answer them in order and most peptide decisions resolve themselves — often before you get to price.

The four questions

1. Has a benefit been demonstrated in humans at all? Not a mechanism. Not a rodent study. A controlled human trial with a clinical endpoint. If the answer is no, the other three questions have nothing to operate on and the expected value of the purchase is unknown.

2. Demonstrated in whom? Every benefit belongs to the population that was studied. Tesamorelin's visceral-fat result came from HIV-associated lipodystrophy. Bremelanotide's desire result came from premenopausal women with a diagnosed disorder. If you are not in that group, you are extrapolating.

3. Over what timeframe, and how big? Trials measure at a point. Skin trials read out at 8–12 weeks, joint trials at 12–24, weight trials at 68–72. An effect that takes six months to appear and is modest when it does is a genuine benefit — and a different purchase from one that transforms something in a fortnight.

4. Does it persist after you stop? This is the question almost nothing else asks, and it changes the arithmetic more than any other. A benefit that requires indefinite treatment is a subscription, not a purchase.

Applying it

Passes all four, with a subscription caveat

Semaglutide and tirzepatide. Benefit demonstrated (yes, large randomised trials — 14.9% mean weight loss in STEP 1[1]). Population (adults with overweight or obesity, plus separate trials in cardiovascular disease, kidney disease and sleep apnoea). Timeframe (68–72 weeks to plateau). Persistence — no: STEP 1 participants regained roughly two-thirds within a year of stopping[2].

Study details: Weight regain and cardiometabolic effects after withdrawal of semaglutide — the STEP 1 trial extension
Study type
rct
Population
STEP 1 participants followed one year after stopping
Sample size
327
Primary result
Participants regained about two-thirds of prior weight loss within a year.
Year
2022
Source
Diabetes, Obesity and Metabolism(link not yet independently re-verified)

Verdict: the strongest evidence in the category, priced as an ongoing commitment rather than a course.

Tesamorelin. Benefit demonstrated (15–18% visceral fat reduction[3]). Population — narrow, HIV-associated lipodystrophy only. Timeframe 26 weeks. Persistence — no, it reverses. Outside that population you are extrapolating on question two.

Bremelanotide (PT-141). Benefit demonstrated in two phase 3 trials, statistically solid and clinically modest. Population narrow. Used as needed rather than continuously, so question four applies differently.

Passes on cost, modest on effect

Collagen peptides. Benefit demonstrated (pooled across 19 randomised trials for skin[4], plus joint-pain trials). Population — general adults, unusually. Timeframe 8–24 weeks. Persistence — untested, but it is an inexpensive food product rather than a drug.

Study details: Effects of hydrolyzed collagen supplementation on skin aging: a systematic review and meta-analysis
Study type
meta-analysis
Population
1,125 participants across 19 randomised trials
Sample size
1125
Primary result
Improvements in skin hydration and elasticity versus placebo.
Year
2021
Source
International Journal of Dermatology(link not yet independently re-verified)

Verdict: the clearest "small but real, and cheap" case on the site. If small-but-real over months is worth it to you, the evidence supports the expectation.

Topical GHK-Cu. Preliminary human evidence in photoaged skin, from small short trials. Reasonable to try; unreasonable to expect retinoid-scale results.

Stops at question one

BPC-157, TB-500, CJC-1295, ipamorelin. No controlled human trial has demonstrated the benefits these are sold for. Reviewers were calling for BPC-157 human trials in 2019 and none has posted results[5]. The secretagogues raise growth hormone, which is a hormone measurement rather than an outcome.

That is not a claim that they do nothing. It is that nobody has measured, so there is no expected benefit to set against the price.

The framework as a table

PeptideBenefit demonstrated?In whomPersists after stopping?
SemaglutideEstablished evidenceYes — large RCTsOverweight/obesity; CVD; CKDNo — most weight regained
TirzepatideEstablished evidenceYes — large RCTsObesity; T2D; sleep apnoeaNo — regain on withdrawal
TesamorelinEstablished evidenceYes — phase 3HIV-associated lipodystrophy onlyNo — reverses
PT-141Established evidenceYes — phase 3Premenopausal women with HSDDUsed as needed
Collagen peptidesPromising evidenceYes — modestGeneral adultsUntested
GHK-Cu (topical)Preliminary evidenceSmall trialsPhotoaged skinUntested
BPC-157Preclinical evidenceNo human trial——
TB-500Preclinical evidenceNo human trial——
CJC-1295Preclinical evidenceHormone levels only——
IpamorelinPreclinical evidenceHormone levels only——

The question behind the question

What we cannot tell you

Whether the trade is worth it for you. That depends on your baseline, your goals, what else you have tried, what you can sustain, and — for the approved drugs — a prescriber's judgement about your history. We can tell you what has been demonstrated, in whom, and for how long. The rest is yours.

Where to go next

Frequently asked questions

Which peptides are actually worth it?
On evidence alone, the approved ones with large trials — semaglutide and tirzepatide for weight and metabolic outcomes, tesamorelin and bremelanotide for their specific approved indications. Whether they are worth it for you is a clinical and financial question only you and a clinician can answer.
Are cheap peptides worth trying since they might work?
The framework's first question is whether a benefit has been demonstrated at all. For BPC-157, TB-500 and growth-hormone secretagogues it has not been, so there is no expected benefit to weigh against cost.
Do I have to take peptides forever?
For the two best-evidenced benefits, effectively yes. Weight loss on GLP-1 drugs and visceral-fat reduction on tesamorelin both largely reverse after stopping.
Is collagen worth it?
It is inexpensive, well tolerated, and produces small measurable improvements in skin and joint-pain measures over 8–24 weeks. Whether small-but-real is worth it to you is a judgement, not a finding.

References

Numbered in order of first use. Study type is shown for every source; see our methodology for how we rank evidence.

  1. 1.

    Wilding JPH, Batterham RL, Calanna S, et al.. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) New England Journal of Medicine, 2021.

    Randomized controlled trialAdults with overweight or obesity without diabetesn = 1961

    Result: Mean weight change −14.9% versus −2.4% placebo at 68 weeks.

    ↑ back to text
  2. 2.

    Wilding JPH, Batterham RL, Davies M, et al.. Weight regain and cardiometabolic effects after withdrawal of semaglutide — the STEP 1 trial extension Diabetes, Obesity and Metabolism, 2022.

    Randomized controlled trialSTEP 1 participants followed one year after stoppingn = 327

    Result: Participants regained about two-thirds of prior weight loss within a year.

    ↑ back to text
  3. 3.

    Falutz J, Mamputu JC, Potvin D, et al.. Effects of tesamorelin in HIV-infected patients with excess abdominal fat — pooled analysis of two phase 3 trials Journal of Clinical Endocrinology & Metabolism, 2010.

    Randomized controlled trialHIV-infected adults with abdominal fat accumulationn = 806

    Result: Visceral adipose tissue reduced 15–18% at 26 weeks; regained on switching to placebo.

    ↑ back to text
  4. 4.

    de Miranda RB, Weimer P, Rossi RC. Effects of hydrolyzed collagen supplementation on skin aging: a systematic review and meta-analysis International Journal of Dermatology, 2021.

    Meta-analysis1,125 participants across 19 randomised trialsn = 1125

    Result: Improvements in skin hydration and elasticity versus placebo.

    ↑ back to text
  5. 5.

    Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing Cell and Tissue Research, 2019.

    Review

    Result: Summarises rodent evidence and concludes human trials are needed and absent.

    ↑ back to text
  6. 6.

    FDA's concerns with unapproved GLP-1 drugs used for weight loss U.S. Food and Drug Administration, 2025.

    Regulatory source

    Result: Describes adverse events reported with compounded products, dosing errors and counterfeit products.

    ↑ back to text

Review status: Editorially reviewed against primary sources. This article was fact-checked against the primary sources listed in the references by our editorial team, and it has not been reviewed by a licensed clinician. It is educational content, not medical advice. Read our editorial policy and methodology. Spotted an error? Tell us.

decision frameworkvaluecostbenefitsevidence

Continue researching

Related analyses, profiles, and research areas

Recommendations are ranked by shared peptides, research areas, evidence level, and topic tags — not by popularity.

Benefits8 min read

Peptide Benefits: What the Evidence Actually Supports

Peptides are credited with dozens of benefits. Some are proven in large trials, some are modest and real, and some have never been tested in a person. This is every major benefit claim, sorted by how strong the human evidence is.

Regulation6 min read

FDA-Approved, Off-Label, Investigational, and Unapproved Peptides

The regulatory status of a peptide is a fact about a decision, not a verdict on the evidence. This guide explains the four categories, what compounding rules changed in 2023–2025, and where every peptide we cover currently sits.

Benefits4 min read

Peptides for Muscle Growth: What the Evidence Supports

Growth-hormone peptides are sold almost entirely on muscle claims. No controlled trial has measured muscle with them. The one peptide with positive lean-mass data is the one nobody markets for it.